pharma remain ga bu
messag pharma sale growth oper medic devic
consum highest oper margin adjust pre-
tax basi point yoy compar medic devic
basi point yoy consum basi point yoy suggest pharma
margin would higher spent basi point increas
full year basi point increas quarter yoy
believ pharma fuel drive engin
report full year earn see note morn
report revenu yoy adjust ep exclud after-
tax intang amort expens special item
consensu ep forecast consensu revenu estim
also provid strong guidanc yet stock djx
today yesterday stock hit high hear anyth
earn call suggest caution acknowledg stock
handsom recent assum activ today bit back fill pharmaceut
sale growth oper much investor discuss
stock action hard point one comment one segment one area
might increas risk number said despit strong fourth quarter growth
guidanc full-year moder appear
springboard higher growth
pharmaceut revenu came consensu vs
consensu estim world-wide pharma sale
repres increas yoy qoq main driver growth
oncolog oper growth yoy lesser degre immunolog
oper growth yoy darzalex continu strong uptak eu
especi prior-lin set qoq darzalex launch countri
eu japan imbruvica qoq show strong global uptak higher market
share growth across multipl indic furthermor imbruvica new
total patient share leader cll well mcl zytiga sale
qoq driven market growth lattitud data zytiga plu prednison
standard hormon therapi men newli diagnos high-risk metastat prostat
cancer lower chanc death strong growth eu japan
manag expect see gener competit zytiga recent
neg ipr rule note current month stay hatch waxman law
expir octob accord manag recent ipr rule
zytiga patent way impact month stay addit intend
defend patent district court turn immunolog remicad sale decreas
qoq mainli attribut increas discounts/reb biosimilar competit
due price remicad declin off-set strong uptak stelara
crohn diseas yoy qoq market growth launch tremfya
believ stelara tremfya like take market share
humira two indic opinion trend could acceler futur
furthermor simponi simponi aria qoq continu strong across major
region lastli turn jnj cv diabet product xarelto grew qoq
increas market share driven access win partial off-set higher discount
manag care/govern channel howev believ eliqui like remain
market share leader invokana grew slightli qoq due increas contract
discount higher util medicaid share loss
page analyst certif import disclosur
guidanc provid sale guidanc adjust ep
reflect expect oper growth rang
ahead current consensu adjust ep line consensu
revenu constant currenc basi adjust ep guidanc rang
reflect oper constant currenc growth
expect oper sale growth rang underli growth exclud
acquisit divestitur approxim acceler
furthermor expect improv pre-tax oper margin approxim
basi point tax rate exclud special item expect
reflect approxim posit impact jnj normal tax
rate result new tax legisl compani plan invest freed money
mainli immedi futur
three point consid anticip apalutamid approv
non-metastat castrate-resist prostat cancer esketamin
approv treatment-resist depress final decemb engag
nanj legend pharmaceut china profit slit except china
legend car-t program treat multipl myeloma paid million
front record expens car-t program target bcma multipl
myeloma fact program file china legend illustr data
patient whose multipl myeloma relaps
previou treatment clinic remiss two month object respons
patient initi know data beyond month lastli exercis
option jointli develop idorsia investig resist hypertens treatment
aprocitentan pay idorsia idia sw up-front decemb well
royalti sale therapi record
 expens
made adjust model base earn result updat guidanc
manag commentari earn call revenu estim increas
forecast strong pharmaceut segment growth
believ pharmaceut segment growth strong due manag commentari
call well new product approv product launch expect total
revenu estim increas previous
previous expens side estim expens increas
sg expens estim reflect increas spend relat
new product launch increas spend result tax reform
increas oper margin base manag guidanc
basi point increas yoy adjust ep estim increas
ep estim increas respect
valuat risk
valuat share current trade ep believ trade
time forward earn base histor multipl compani
earn therefor maintain neutral rate ep estim increas
ep estim increas respect
upsid risk neutral rate includ posit turn either md
consum busi favor commerci zytiga darzalex
imbruvica see import revenu driver upcom year
downsid risk includ biosimilar competit remicad jnj largest
product term gross sale stronger fx headwind anticip product
page analyst certif import disclosur
million except per-shar figur
good sold total
adjust non-gaap measur
reconcili one-time/non-gaap item
adjust incom tax
net impact non-gaap reconcili
impact adjust
compani report guggenheim secur llc estim
page analyst certif import disclosur
